Case Study: Designing Cancer Drugs: Development of Gleevec

Chronic myelogenous leukemia (CML) is an unusual cancer because a single mutation is initially responsible and we know the function of the mutated gene. The mutant gene, called Bcr-Abl, encodes a kinase in a signal transduction pathway.

Click NEXT to learn about the
Bcr-Abl mutation.

arrow Next

Graphic: Signal Transduction Pathway
Drug Development Timeline